Skip to content

Trial · Interventional

CompletedPhase 2Registry data

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

NCTNCT01508949 (opens ClinicalTrials.gov in a new tab)Other idNN2211-1333
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 2
Enrollment
35 participants (actual)
Sponsor
Novo Nordisk A/S · Industry
Design
Randomized · Double masking
Countries
1 country

Denmark

Start
Jun 2001
Primary completion
Mar 2002
Completion
Mar 2002
First posted
12 Jan 2012 (estimated)
Last update posted
2 Nov 2023
Conditions
Diabetes · Diabetes Mellitus, Type 2

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
200120022003
  1. Ph 2

    Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

    NCT01508949

    Jun 2001 to Mar 2002

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This trial is conducted in Europe. The aim of the trial is to investigate the effect of NNC 90-1170 (liraglutide) on weight and appetite in obese subjects with type 2 diabetes treated with diet and/or sulphonylurea or repaglinide.

Interventions

  • liraglutideDrug
  • placeboDrug

Arms2

  • Experimental

    NNC 90-1170

  • Placebo comparator

    Placebo

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Change in weight

Secondary outcomes(8)

  1. Total fat mass (assessed by use of DEXA (dual energy X-ray absorptiometry) scan)

  2. Waist circumference

  3. Spontaneous energy intake assessed in connection to the ad libitum lunch meal

  4. Appetite assessed in connection with the fixed breakfast meal (assessed by the use of VAS (visual analogue scale))

  5. Gastric emptying rate

  6. Energy expenditure

  7. HbA1c (Glycosylated Haemoglobin)

  8. Adverse events

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2004

6 results

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.

Harder et al. 2004Diabetes carecited by 176

PMID 15277417DOI 10.2337/diacare.27.8.1915PUB-15277417

Rights unknown6 results
Source linkSee results (6)

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Type 2 diabetes mellitus * Diet treated and/or subjects in monotherapy with sulphonylurea or repaglinide * HbA1c for diet treated subjects 6.5-12%, both inclusive * HbA1c for sulphonylurea or repaglinide treated subjects maximum 10% * Body mass index (BMI) at least 27 kg/m\^2 * Euthyroid subjects * Fasting blood glucose 7-14 mmol/l Exclusion Criteria: * Impaired liver function * Impaired renal function * Cardiac problems * Uncontrolled treated/untreated hypertension * Recurrent severe hypoglycaemia as judged by the Investigator * Known or suspected allergy to trial product or related products * Use of any drug (except for OHAs (oral hypoglycaemic agents), which in the Investigator's opinion could interfere with the glucose level or body weight. Stable doses, for 3 months or greater, of thyroid hormone replacement are allowed

PepBank is a research reference. Talk to a doctor before you use any peptide.